glp-1 agonists and sglt2 inhibitors combination Complementary Yet Distinct Roles of Receptor in Cardiovascular Risk Reduction Frontiers | A decade of

2.2 Indications The currently approved indications for these agents include: Type 2 diabetes mellitus Overweight and obesity Beyond diabetes and obesity, further indications under investigation for GLP1 RAs include: Osteoarthritis Obstructive sleep apnea Metabolic dysfunction-associated steatotic liver disease Metabolic dysfunction-associated steatohepatitis 2.3 Benefits and Harms of Continuation/Discontinuation in the Perioperative Period: 2.3.1 Benefits: According to the guidelines, the acute use of these drugs may offer benefits based on published data: Improved perioperative glycemic control Lower postoperative insulin requirements Reduced risk of hypoglycemia These benefits may lead to reduced complications associated with hyperglycemia (such as a shorter hospital stay, fewer surgical site infections, less acute kidney injury, fewer acute coronary syndromes, reduced critical care admissions, and shorter durations on a ventilator) Improved cardiovascular outcomes 2.3.2 Harms There is an increased risk of pulmonary aspiration

Many professionals recommend weekly sessions initially, followed by maintenance doses based on desired results

Yet a recent JAMA Cardiology study found that among Americans 65 and up with diabetes, about 60% discontinued semaglutide within a year

The review evaluates these drugs across diverse patient populations, including those with clinically established T2D, obesity, CVD, and CKD

Female age trumps all: over 40, rates fall sharply for everyone